CNS Market Trends, 2007 to 2010

Table of Contents

Executive Summary

• Overview
• Key disease markets
• Key drug classes
• Key products
• Key companies
• Key trends and opportunities

Chapter 1. Overview of Global CNS Market

• Global CNS market
• Report overview
  • Methodology
  • Sources

Chapter 2. Key CNS Disease Markets

• Key CNS markets
  • Disease burden
  • CNS prevalence
  • CNS mortality
• CNS epidemiology
  • ADHD (Attention Deficit Hyperactivity Disorder)
  • Alzheimer' s disease
  • Depression
  • Epilepsy
  • Migraine
  • Parkinson' s disease
  • Schizophrenia

Chapter 3. Key CNS Drug Classes

• Key drug classifications
• Anti-depressants drug class
  • Leading anti-depressant drugs
• Anti-psychotics drug class
  • Leading anti-psychotics
• Epilepsy drug class
  • Leading epilepsy drugs
• Alzheimer' s disease drug class
  • Leading Alzheimer' s disease drugs
• Migraine drug class
  • Leading migraine drugs
• ADHD drug class
  • Leading ADHD drugs
• Parkinson' s disease drug class
  • Leading Parkinson' s disease drugs
• Selected other drug classes
• Leading selected other CNS drugs

Chapter 4. Key CNS Products

• Leading products
• Top 10 leading CNS drugs
  • Zyprexa (olanzapine)
  • Risperdal (risperidone)
  • Effexor (venlafaxine)
  • Zoloft (sertraline)
  • Seroquel (quetiapine)
  • Lexapro/ Cipralex (escitalopram)
  • Aricept (donepezil)
  • Topamax (topiramate)
  • Lamictal (lamotrigine)
  • Wellbutrin (bupropion)

Chapter 5. Key Companies Involved in CNS

• Major CNS players
• Leading companies
  • Johnson & Johnson
  • Pfizer
  • Eli Lilly
  • GlaxoSmithKline
  • AstraZeneca
  • Wyeth
  • Novartis
  • Forest
  • Abbott
  • Sanofi-Aventis

Chapter 6. Key Trends and Opportunities in CNS

• Key disease market forecasts
  • Global markets
  • CNS sites
• Key drug class forecasts
  • Anti-depressants
  • Anti-psychotics
  • Epilepsy
  • Alzheimer' s disease
  • Migraine
  • ADHD
  • Parkinson' s disease
• Selected others
• Key product forecasts
  • Zyprexa (olanzapine)
  • Risperdal (risperidone)
  • Effexor (venlafaxine)
  • Zoloft (sertraline)
  • Seroquel (quetiapine)
  • Lexapro/ Cipralex (escitalopram)
  • Aricept (donepezil)
  • Topamax (topiramate)
  • Lamictal (lamotrigine)
  • Wellbutrin (bupropion)
  • Forecast patent expiries
• Company forecasts in the CNS area
  • Johnson & Johnson
  • Pfizer
  • Eli Lilly
  • GlaxoSmithKline
  • AstraZeneca
  • Wyeth
  • Novartis
  • Forest
  • Abbott
  • Sanofi-Aventis

Appendix

• Proprietary data sources
• Product Trends Database
• R&D Trends Database
• Company Trends Database
• Top 48 CNS products
• Top 15 pharmaceutical companies by CNS sales

Figures

• Figure 1: Global CNS market, 2003-2005
• Figure 2: Report structure
• Figure 3: Disease burden for CNS in seven major pharmaceutical markets, 2005
• Figure 4: Prevalence for CNS in seven major pharmaceutical markets, 2005
• Figure 5: CNS deaths in seven major pharmaceutical markets, 2005
• Figure 6: CNS epidemiology in seven major markets, 2005
• Figure 7: ADHD epidemiology in seven major markets, 2005
• Figure 8: Alzheimer' s disease epidemiology in seven major markets, 2005
• Figure 9: Depression epidemiology in seven major markets, 2005
• Figure 10: Epilepsy epidemiology in seven major markets, 2005
• Figure 11: Migraine epidemiology in seven major markets, 2005
• Figure 12: Parkinson' s disease epidemiology in seven major markets, 2005
• Figure 13: Schizophrenia epidemiology in seven major markets, 2005
• Figure 14: Global CNS market by drug class, 2005
• Figure 15: Global CNS market by drug class, 2003-2005
• Figure 16: Global CNS market trends by drug class, 2004-2005
• Figure 17: Anti-depressants drugs market, 2003-2005
• Figure 18: Leading anti-depressant drugs by approval date, 1980-2005
• Figure 19: Anti-psychotics drugs market, 2003-2005
• Figure 20: Leading anti-psychotics by approval date, 1989-2005
• Figure 21: Epilepsy drugs market, 2003-2005
• Figure 22: Leading epilepsy drugs by approval date, 1968-2005
• Figure 23: Alzheimer' s disease drugs market, 2003-2005
• Figure 24: Leading Alzheimer' s disease drugs by approval date, 1996-2005
• Figure 25: Migraine drugs market, 2003-2005
• Figure 26: Leading migraine drugs by approval date, 1992-2005
• Figure 27: ADHD drugs market, 2003-2005
• Figure 28: Leading ADHD drugs by approval date, 1996-2005
• Figure 29: Parkinson' s disease market, 2003-2005
• Figure 30: Leading Parkinson' s disease drugs by approval date, 1997-2005
• Figure 31: Selected others market, 2003-2005
• Figure 32: Leading selected other CNS drugs by approval date, 1968-2005
• Figure 33: Top 10 CNS products by global sales, 2005
• Figure 34: Top 10 companies by global CNS sales, 2005
• Figure 35: Top 10 companies by global CNS market share, 2005
• Figure 36: Top 10 companies by global CNS sales, 2004-2005
• Figure 37: CNS incidence forecasts by geographic market, 2005-2010
• Figure 38: CNS incidence forecasts by disease market, 2005-2010
• Figure 39: Global CNS market forecast, 2003-2010
• Figure 40: Global CNS market forecasts by drug class, 2003-2010
• Figure 41: Top 10 CNS drugs by forecast sales, 2010
• Figure 42: Zyprexa (olanzapine) forecast sales, 2003-2010
• Figure 43: Risperdal (risperidone) forecast sales, 2003-2010
• Figure 44: Effexor (venlafaxine) forecast sales, 2003-2010
• Figure 45: Zoloft (sertraline) forecast sales, 2003-2010
• Figure 46: Seroquel (quetiapine) forecast sales, 2003-2010
• Figure 47: Lexapro/ Cipralex (escitalopram) forecast sales, 2003-2010
• Figure 48: Aricept (donepezil) forecast sales, 2003-2010
• Figure 49: Topamax (topiramate) forecast sales, 2003-2010
• Figure 50: Lamictal (lamotrigine) forecast sales, 2003-2010
• Figure 51: Wellbutrin (bupropion) forecast sales, 2003-2010
• Figure 52: Forecast patent expiries by 2005 global sales, 2006-2015
• Figure 53: Top ten companies by CNS sales trends, 2005-2010

Tables

• Table 1: Global CNS market trends by drug class, 2003-2005
• Table 2: Leading anti-depressant drugs, 2005
• Table 3: Anti-depressants market trends, 2003-2005
• Table 4: Leading anti-psychotics, 2005
• Table 5: Anti-psychotics market trends, 2003-2005
• Table 6: Leading epilepsy drugs, 2005
• Table 7: Epilepsy drug market trends, 2003-2005
• Table 8: Leading Alzheimer' s disease drugs, 2005
• Table 9: Alzheimer' s disease drug market trends, 2003-2005
• Table 10: Leading migraine drugs, 2005
• Table 11: Migraine drugs market trends, 2003-2005
• Table 12: Leading ADHD drugs, 2005
• Table 13: ADHD drugs market trends, 2003-2005
• Table 14: Leading Parkinson' s disease drugs, 2005
• Table 15: Parkinson' s disease market trends, 2003-2005
• Table 16: Leading selected other CNS drugs, 2005
• Table 17: selected others market trends, 2003-2005
• Table 18: Top 20 CNS products by global sales, 2003-2005
• Table 19: Zyprexa (olanzapine) profile, 2005
• Table 20: Risperdal (risperidone) profile, 2005
• Table 21: Effexor (venlafaxine) profile, 2005
• Table 22: Zoloft (sertraline) profile, 2005
• Table 23: Seroquel (quetiapine) profile, 2005
• Table 24: Lexapro (escitalopram) profile, 2005
• Table 25: Aricept (donepezil) profile, 2005
• Table 26: Topamax (topiramate) profile, 2005
• Table 27: Lamictal (lamotrigine) profile, 2005
• Table 28: Wellbutrin (bupropion) profile, 2005
• Table 29: Top 10 companies by global CNS sales, 2003-2005
• Table 30: Johnson & Johnson profile, 2005
• Table 31: Johnson & Johnson pipeline, 2005
• Table 32: Pfizer profile, 2005
• Table 33: Pfizer CNS pipeline, 2005
• Table 34: Eli Lilly profile, 2005
• Table 35: Eli Lilly CNS pipeline, 2005
• Table 36: GlaxoSmithKline profile, 2005
• Table 37: GlaxoSmithKline CNS pipeline, 2005
• Table 38: AstraZeneca profile, 2005
• Table 39: AstraZeneca CNS pipeline, 2005
• Table 40: Wyeth profile, 2005
• Table 41: Wyeth CNS pipeline, 2005
• Table 42: Novartis profile, 2005
• Table 43: Novartis CNS pipeline, 2005
• Table 44: Forest profile, 2005
• Table 45: Forest CNS pipeline, 2005
• Table 46: Abbott profile, 2005
• Table 47: Abbott CNS pipeline, 2005
• Table 48: Sanofi-Aventis profile, 2005
• Table 49: Sanofi-Aventis CNS pipeline, 2005
• Table 50: Global CNS market forecasts by drug class, 2003-2010
• Table 51: Top 10 CNS drugs forecasts, 2003-2010
• Table 52: Top 10 companies by CNS sales forecasts, 2005-2010
• Table 53: Top 48 CNS products by global pharmaceutical sales, 2003-2005
• Table 54: Top 15 companies by global CNS sales, 2003-2005